| Bioactivity | Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research[1][2][3]. |
| Invitro | Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro[1].Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis[1]. Cell Cycle Analysis[1] Cell Line: |
| Name | Oblimersen |
| CAS | 190977-41-4 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |